Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2015
At a glance
- Drugs GPX 150 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Gem Pharmaceuticals
- 12 Feb 2015 Results published in the Investigational New Drugs.
- 04 Aug 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 08 Jun 2011 Additional lead center and company (Gem Pharmaceuticals) added as associations field.